5-Chloro-N-(2,4-dimethoxybenzyl)-2-fluoro-4-{[3-pyridazin-4-yl-2'-(trifluoromethyl)biphenyl-4-yl]oxy}-N-1,3,4-thiadiazol-2-ylbenzenesulfonamide → HCID 56600582, Verbindung

HRID 1619588Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 1619588
[Cl:1][C:2]1[C:3]([O:29][C:30]2[CH:35]=[CH:34][C:33]([C:36]3[CH:41]=[CH:40][CH:39]=[CH:38][C:37]=3[C:42]([F:45])([F:44])[F:43])=[CH:32][C:31]=2[C:46]2[CH:51]=[CH:50][N:49]=[N:48][CH:47]=2)=[CH:4][C:5]([F:28])=[C:6]([S:8]([N:11](CC2C=CC(OC)=CC=2OC)[C:12]2[S:13][CH:14]=[N:15][N:16]=2)(=[O:10])=[O:9])[CH:7]=1>Cl.O1CCOCC1>[Cl:1][C:2]1[C:3]([O:29][C:30]2[CH:35]=[CH:34][C:33]([C:36]3[CH:41]=[CH:40][CH:39]=[CH:38][C:37]=3[C:42]([F:43])([F:44])[F:45])=[CH:32][C:31]=2[C:46]2[CH:51]=[CH:50][N:49]=[N:48][CH:47]=2)=[CH:4][C:5]([F:28])=[C:6]([S:8]([NH:11][C:12]2[S:13][CH:14]=[N:15][N:16]=2)(=[O:10])=[O:9])[CH:7]=1

Komponenten

4

Versuchsvorschrift

5-Chloro-N-(2,4-dimethoxybenzyl)-2-fluoro-4-{[3-pyridazin-4-yl-2′-(trifluoromethyl)biphenyl-4-yl]oxy}-N-1,3,4-thiadiazol-2-ylbenzenesulfonamide (Preparation 23, 339 mg, 0.45 mmol) was dissolved in a 4M solution of hydrogen chloride in 1,4-dioxane (10 mL). The mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated in vacuo and the resulting residue purified by reverse phase preparative HPLC (Trilution method) to afford the title compound as a white solid (75 mg, 27%).

Aufarbeitung

  1. concentrationThe reaction mixture was concentrated in vacuo
  2. customthe resulting residue purified by reverse phase preparative HPLC (Trilution method)

Quellen und Nachweise

ORD-Eintrag
ord-a1b03eb81abd4cc9af0ab1e86d152057
Quelldatensatz
uspto-grants-2014_07
Patentnummer
US08772293B2

Notizen zur Reaktion

Wird geladen…